Oncolytic viruses driven by tumor-specific promoters.
Curr Cancer Drug Targets
; 7(2): 181-9, 2007 Mar.
Article
en En
| MEDLINE
| ID: mdl-17346110
ABSTRACT
Oncolytic viruses can selectively replicate in and lead to tumor cell lysis with minimal infection/replication potential in adjoining non-neoplastic tissue. Because of paramount safety concerns, first-generation oncolytic viruses were designed to be significantly attenuated in their lytic potential. Results from recent clinical trials have revealed the safety of this approach, but have underscored the urgency for design and testing of more tumor-selective and -potent viruses to realize the full therapeutic potential of this revolutionary treatment modality. With the discovery of various molecular/genetic changes associated with neoplasia, tumor-specific transcriptional targeting of viral virulence is being tapped to generate tumor- and tissue-specific variants. This review will focus on the various strategies exploited to generate viruses whose virulence is governed by tumor-specific transcriptional events.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Transcripción Genética
/
Regiones Promotoras Genéticas
/
Virus Oncolíticos
/
Viroterapia Oncolítica
/
Proteínas de Neoplasias
/
Neoplasias
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Cancer Drug Targets
Asunto de la revista:
ANTINEOPLASICOS
/
NEOPLASIAS
Año:
2007
Tipo del documento:
Article
País de afiliación:
Estados Unidos